Cancers | Free Full-Text | Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer
ASCO Guideline Highlights Newest Breakthroughs in the Treatment of Metastatic Colorectal Cancer - The ASCO Post
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer | Nature Medicine
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort | Research Communities by Springer Nature
The current treatment paradigm for patients with metastatic colorectal... | Download Scientific Diagram
World-first confirmation of standard treatment for RAS wild-type colorectal cancer －Paper published in JAMA－ | National Cancer Center Japan
Seyda Gunduz on X: "#PARADIGM trial First-line Panitumab is superior to bevacizumab in the left-sided RAS wild metastatic colon cancer #ASCO22 https://t.co/6XLAWIK1c2" / X
Colon cancer chemotherapy trials | PPT
RAS野生型の切除不能進行再発大腸癌の一次治療においてPanitumumab＋mFOLFOX6療法とBevacizumab＋mFOLFOX6療法を比較した無作為化第III相試験（ PARADIGM試験） | GI cancer-netR 海外学会速報レポート
Metastatic Colon and Rectal Cancer Updates, ASCO 2022
Frontiers | Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements
Yüksel Ürün on X: "PARADIGM trial: 1st-L treatment in patients with RAS wild-type metastatic colorectal cancer 🔸PAN + mFOLFOX6 >> BEV + mFOLFOX6, HR 0.82 for OS (in left-sided tumors) 🔸No difference
Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer - ScienceDirect
Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management - ScienceDirect
Therapeutic landscape and future direction of metastatic colorectal cancer | Nature Reviews Gastroenterology & Hepatology
PARADIGM Study Design & Clinical Data | Vectibix® (panitumumab)
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial | Nature Medicine
Frontiers | Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer
Current Oncology | Free Full-Text | Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer
Comparison of current versus the evolving ctDNA-guided adjuvant therapy... | Download Scientific Diagram
Seyda Gunduz on X: "#PARADIGM trial First-line Panitumab is superior to bevacizumab in the left-sided RAS wild metastatic colon cancer #ASCO22 https://t.co/6XLAWIK1c2" / X
PARADIGM Study Design & Clinical Data | Vectibix® (panitumumab)
Study design of the FIRE-4 (AIO KRK-0114) trial. | Download Scientific Diagram
IJMS | Free Full-Text | Total Neoadjuvant Treatment for Locally Advanced Rectal Cancer Patients: Where Do We Stand?
Cancers | Free Full-Text | ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm
PARADIGM - Slideset Download - Clinical Oncology 2022 | CCO
Hitting the Target in HER2-Positive Metastatic Colorectal Cancer | PPT
